GlassScriptPhysician profile
Terrence S Peppy
NPI 1306836317
$7,219.78
in general payments reported to CMS, 2019-2025
35 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $387 · 2021: $873 · 2022: $1,366 · 2023: $1,210 · 2024: $1,003 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Consulting Fee: $700 · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.06 |
| Consulting Fee | $700.00 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $2,120.94 | 2022-2025 | |
| Abbvie INC. | $953.72 | 2019-2023 | |
| Exeltis, USA INC. | $650.69 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $550.19 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $447.12 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Ethicon US, LLC | $295.13 | 2019-2024 | Megadyne |
| Bayer Healthcare Pharmaceuticals INC. | $265.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $155.42 | 2019-2024 | Gardasil 9, Gardasil |
| Biogen, INC. | $144.52 | 2025 | Zurzuvae |
| Millicent US INC | $138.05 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Gynesonics, INC. | $133.11 | 2021-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Minerva Surgical, INC | $130.95 | 2019 | |
| Exact Sciences Corporation | $101.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medical Device Business Services, INC. | $100.14 | 2020 | |
| Organon LLC | $93.83 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $85.48 | 2019-2022 | |
| Allergan, INC. | $83.99 | 2019-2020 | |
| Avion Pharmaceuticals | $80.90 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $78.59 | 2023-2024 | Myfembree, Gemtesa |
| Pfizer INC. | $78.03 | 2021-2024 | |
| Amgen INC. | $72.91 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $61.44 | 2019 | |
| Amag Pharmaceuticals, INC. | $61.15 | 2019 | |
| Aspira Women'S Health INC | $58.39 | 2021 | |
| Myriad Women'S Health, INC. | $53.08 | 2023 | Myrisk |
| Duchesnay USA Incorporated | $42.35 | 2019 | |
| Mayne Pharma Commercial LLC | $40.99 | 2021-2023 | |
| Agile Therapeutics, INC. | $31.73 | 2022-2023 | Twirla |
| Myovant Sciences INC. | $25.80 | 2022 | |
| Shield Therapeutics INC | $19.06 | 2025 | |
| Sanofi Pasteur INC. | $15.39 | 2020 | |
| Karl Storz Endoscopy-America | $14.87 | 2019 | |
| Roche Diagnostics Corporation | $11.86 | 2021 | |
| Avanos Medical | $11.61 | 2020 | |
| Daiichi Sankyo INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,610,925.98 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Peppy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.